OKYO
OKYO Pharma Limited (NASDAQ)
Healthcare — Biotechnology
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Price History
Fundamentals
| Market Cap | $78.72M |
| P/E Ratio (TTM) | - |
| Forward P/E | -7.50 |
| EPS (TTM) | $-0.11 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $9.00 |
| Analysts | 3 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 51.5 |
| Beta | 0.02 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $3.35 |
| 52-Week Low | $1.42 |
| 50-Day Avg | $1.60 |
| 200-Day Avg | $1.92 |
| Avg Volume | 66.1K |
| Volume | 40.5K |
Performance Analysis
NEUTRALOKYO presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:24 UTC
Back to Screener Export Report